Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Kidney harvesting and metabolite extraction for metabolomics studies in rodents.

Maksimovic I, Zhang S, Vuckovic I, Irazabal MV.

Methods Cell Biol. 2019;154:15-29. doi: 10.1016/bs.mcb.2019.05.009. Epub 2019 Jul 26.

PMID:
31493816
2.

Presymptomatic Screening for Intracranial Aneurysms in Patients with Autosomal Dominant Polycystic Kidney Disease.

Sanchis IM, Shukoor S, Irazabal MV, Madsen CD, Chebib FT, Hogan MC, El-Zoghby Z, Harris PC, Huston J, Brown RD, Torres VE.

Clin J Am Soc Nephrol. 2019 Aug 7;14(8):1151-1160. doi: 10.2215/CJN.14691218. Epub 2019 Jul 30.

PMID:
31362991
3.

Three-dimensional NMR microscopy of zebrafish specimens.

Kline TL, Sussman CR, Irazabal MV, Mishra PK, Pearson EA, Torres VE, Macura SI.

NMR Biomed. 2019 Jan;32(1):e4031. doi: 10.1002/nbm.4031. Epub 2018 Nov 15.

4.

CKD Due to a Novel Mitochondrial DNA Mutation: A Case Report.

Fervenza FC, Gavrilova RH, Nasr SH, Irazabal MV, Nath KA.

Am J Kidney Dis. 2019 Feb;73(2):273-277. doi: 10.1053/j.ajkd.2018.06.032. Epub 2018 Oct 8. Review.

PMID:
30309714
5.

Total Kidney Volume and Autosomal Dominant Polycystic Kidney Disease: A Long-Standing Relationship.

Irazabal MV, Torres VE.

Am J Nephrol. 2018;48(1):65-66. doi: 10.1159/000491026. Epub 2018 Aug 2. No abstract available.

6.

Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.

Edwards ME, Chebib FT, Irazabal MV, Ofstie TG, Bungum LA, Metzger AJ, Senum SR, Hogan MC, El-Zoghby ZM, Kline TL, Harris PC, Czerwiec FS, Torres VE.

Clin J Am Soc Nephrol. 2018 Aug 7;13(8):1153-1161. doi: 10.2215/CJN.01520218. Epub 2018 Jul 19. Erratum in: Clin J Am Soc Nephrol. 2019 Jun 7;14(6):910.

7.

Autosomal Dominant Polycystic Kidney Patients May Be Predisposed to Various Cardiomyopathies.

Chebib FT, Hogan MC, El-Zoghby ZM, Irazabal MV, Senum SR, Heyer CM, Madsen CD, Cornec-Le Gall E, Behfar A, Harris PC, Torres VE.

Kidney Int Rep. 2017 Jun 6;2(5):913-923. doi: 10.1016/j.ekir.2017.05.014. eCollection 2017 Sep.

8.

Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial.

Cornec-Le Gall E, Blais JD, Irazabal MV, Devuyst O, Gansevoort RT, Perrone RD, Chapman AB, Czerwiec FS, Ouyang J, Heyer CM, Senum SR, Le Meur Y, Torres VE, Harris PC.

Nephrol Dial Transplant. 2018 Apr 1;33(4):645-652. doi: 10.1093/ndt/gfx188.

9.

Generation and phenotypic characterization of Pde1a mutant mice.

Wang X, Yamada S, LaRiviere WB, Ye H, Bakeberg JL, Irazabal MV, Chebib FT, van Deursen J, Harris PC, Sussman CR, Behfar A, Ward CJ, Torres VE.

PLoS One. 2017 Jul 27;12(7):e0181087. doi: 10.1371/journal.pone.0181087. eCollection 2017.

10.

Quantitative MRI of kidneys in renal disease.

Kline TL, Edwards ME, Garg I, Irazabal MV, Korfiatis P, Harris PC, King BF, Torres VE, Venkatesh SK, Erickson BJ.

Abdom Radiol (NY). 2018 Mar;43(3):629-638. doi: 10.1007/s00261-017-1236-y.

11.

The regulatory 1α subunit of protein kinase A modulates renal cystogenesis.

Ye H, Wang X, Constans MM, Sussman CR, Chebib FT, Irazabal MV, Young WF Jr, Harris PC, Kirschner LS, Torres VE.

Am J Physiol Renal Physiol. 2017 Sep 1;313(3):F677-F686. doi: 10.1152/ajprenal.00119.2017. Epub 2017 Jun 14.

12.

Performance of the CKD-EPI Equation to Estimate GFR in a Longitudinal Study of Autosomal Dominant Polycystic Kidney Disease.

Shen C, Landsittel D, Irazabal MV, Yu AS, Chapman AB, Mrug M, Grantham JJ, Bae KT, Bennett WM, Flessner MF, Torres VE; CRISP Investigators.

Am J Kidney Dis. 2017 Mar;69(3):482-484. doi: 10.1053/j.ajkd.2016.10.021. Epub 2016 Dec 24. No abstract available.

13.

Role of Renal Sinus Adipose Tissue in Obesity-induced Renal Injury.

Irazabal MV, Eirin A.

EBioMedicine. 2016 Nov;13:21-22. doi: 10.1016/j.ebiom.2016.11.002. Epub 2016 Nov 8. No abstract available.

14.

Prognostic Enrichment Design in Clinical Trials for Autosomal Dominant Polycystic Kidney Disease: The TEMPO 3:4 Clinical Trial.

Irazabal MV, Blais JD, Perrone RD, Gansevoort RT, Chapman AB, Devuyst O, Higashihara E, Harris PC, Zhou W, Ouyang J, Czerwiec FS, Torres VE.

Kidney Int Rep. 2016 Aug 6;1(4):213-220. doi: 10.1016/j.ekir.2016.08.001. eCollection 2016 Nov.

15.

Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial.

Irazabal MV, Abebe KZ, Bae KT, Perrone RD, Chapman AB, Schrier RW, Yu AS, Braun WE, Steinman TI, Harris PC, Flessner MF, Torres VE; HALT Investigators.

Nephrol Dial Transplant. 2017 Nov 1;32(11):1857-1865. doi: 10.1093/ndt/gfw294.

16.

Inherited renal cystic diseases.

Kim B, King BF Jr, Vrtiska TJ, Irazabal MV, Torres VE, Harris PC.

Abdom Radiol (NY). 2016 Jun;41(6):1035-51. doi: 10.1007/s00261-016-0754-3. Review.

PMID:
27167233
17.

Native Nephrectomy in Renal Transplant Recipients with Autosomal Dominant Polycystic Kidney Disease.

Chebib FT, Prieto M, Jung Y, Irazabal MV, Kremers WK, Dean PG, Rea DJ, Cosio FG, Torres VE, El-Zoghby ZM.

Transplant Direct. 2015 Nov 1;1(10):e43. Epub 2015 Nov 18.

18.

Effect of genotype on the severity and volume progression of polycystic liver disease in autosomal dominant polycystic kidney disease.

Chebib FT, Jung Y, Heyer CM, Irazabal MV, Hogan MC, Harris PC, Torres VE, El-Zoghby ZM.

Nephrol Dial Transplant. 2016 Jun;31(6):952-60. doi: 10.1093/ndt/gfw008. Epub 2016 Feb 29.

19.

Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease.

Heyer CM, Sundsbak JL, Abebe KZ, Chapman AB, Torres VE, Grantham JJ, Bae KT, Schrier RW, Perrone RD, Braun WE, Steinman TI, Mrug M, Yu AS, Brosnahan G, Hopp K, Irazabal MV, Bennett WM, Flessner MF, Moore CG, Landsittel D, Harris PC; HALT PKD and CRISP Investigators.

J Am Soc Nephrol. 2016 Sep;27(9):2872-84. doi: 10.1681/ASN.2015050583. Epub 2016 Jan 28.

20.

Modulation of Polycystic Kidney Disease Severity by Phosphodiesterase 1 and 3 Subfamilies.

Ye H, Wang X, Sussman CR, Hopp K, Irazabal MV, Bakeberg JL, LaRiviere WB, Manganiello VC, Vorhees CV, Zhao H, Harris PC, van Deursen J, Ward CJ, Torres VE.

J Am Soc Nephrol. 2016 May;27(5):1312-20. doi: 10.1681/ASN.2015010057. Epub 2015 Sep 15.

21.

Automatic total kidney volume measurement on follow-up magnetic resonance images to facilitate monitoring of autosomal dominant polycystic kidney disease progression.

Kline TL, Korfiatis P, Edwards ME, Warner JD, Irazabal MV, King BF, Torres VE, Erickson BJ.

Nephrol Dial Transplant. 2016 Feb;31(2):241-8. doi: 10.1093/ndt/gfv314. Epub 2015 Aug 31.

22.

Efficacy of 4 Years of Octreotide Long-Acting Release Therapy in Patients With Severe Polycystic Liver Disease.

Hogan MC, Masyuk T, Bergstralh E, Li B, Kremers WK, Vaughan LE, Ihrke A, Severson AL, Irazabal MV, Glockner J, LaRusso NF, Torres VE.

Mayo Clin Proc. 2015 Aug;90(8):1030-7. doi: 10.1016/j.mayocp.2015.05.011. Epub 2015 Jul 9.

23.

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring.

Irazabal MV, Mishra PK, Torres VE, Macura SI.

J Vis Exp. 2015 Jun 23;(100):e52757. doi: 10.3791/52757.

24.

A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR).

Fervenza FC, Canetta PA, Barbour SJ, Lafayette RA, Rovin BH, Aslam N, Hladunewich MA, Irazabal MV, Sethi S, Gipson DS, Reich HN, Brenchley P, Kretzler M, Radhakrishnan J, Hebert LA, Gipson PE, Thomas LF, McCarthy ET, Appel GB, Jefferson JA, Eirin A, Lieske JC, Hogan MC, Greene EL, Dillon JJ, Leung N, Sedor JR, Rizk DV, Blumenthal SS, Lasic LB, Juncos LA, Green DF, Simon J, Sussman AN, Philibert D, Cattran DC; Mentor Consortium group.

Nephron. 2015;130(3):159-68. doi: 10.1159/000430849. Epub 2015 Jun 12.

PMID:
26087670
25.

Volume regression of native polycystic kidneys after renal transplantation.

Jung Y, Irazabal MV, Chebib FT, Harris PC, Dean PG, Prieto M, Cosio FG, El-Zoghby ZM, Torres VE.

Nephrol Dial Transplant. 2016 Jan;31(1):73-9. doi: 10.1093/ndt/gfv227. Epub 2015 Jun 4.

26.

Utilizing magnetization transfer imaging to investigate tissue remodeling in a murine model of autosomal dominant polycystic kidney disease.

Kline TL, Irazabal MV, Ebrahimi B, Hopp K, Udoji KN, Warner JD, Korfiatis P, Mishra PK, Macura SI, Venkatesh SK, Lerman LO, Harris PC, Torres VE, King BF, Erickson BJ.

Magn Reson Med. 2016 Apr;75(4):1466-73. doi: 10.1002/mrm.25701. Epub 2015 May 13.

27.

Histiocytic glomerulopathy associated with macrophage activation syndrome.

Eirin A, Irazabal MV, Fervenza FC, Sethi S.

Clin Kidney J. 2015 Apr;8(2):157-60. doi: 10.1093/ckj/sfv010. Epub 2015 Feb 17.

28.

Effects of hydration in rats and mice with polycystic kidney disease.

Hopp K, Wang X, Ye H, Irazabal MV, Harris PC, Torres VE.

Am J Physiol Renal Physiol. 2015 Feb 1;308(3):F261-6. doi: 10.1152/ajprenal.00345.2014. Epub 2014 Dec 10.

29.

Identification of Biomarkers for PKD1 Using Urinary Exosomes.

Hogan MC, Bakeberg JL, Gainullin VG, Irazabal MV, Harmon AJ, Lieske JC, Charlesworth MC, Johnson KL, Madden BJ, Zenka RM, McCormick DJ, Sundsbak JL, Heyer CM, Torres VE, Harris PC, Ward CJ.

J Am Soc Nephrol. 2015 Jul;26(7):1661-70. doi: 10.1681/ASN.2014040354. Epub 2014 Dec 4.

30.

Novel therapeutic approaches to autosomal dominant polycystic kidney disease.

LaRiviere WB, Irazabal MV, Torres VE.

Transl Res. 2015 Apr;165(4):488-98. doi: 10.1016/j.trsl.2014.11.003. Epub 2014 Nov 13. Review.

31.

Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials.

Irazabal MV, Rangel LJ, Bergstralh EJ, Osborn SL, Harmon AJ, Sundsbak JL, Bae KT, Chapman AB, Grantham JJ, Mrug M, Hogan MC, El-Zoghby ZM, Harris PC, Erickson BJ, King BF, Torres VE; CRISP Investigators.

J Am Soc Nephrol. 2015 Jan;26(1):160-72. doi: 10.1681/ASN.2013101138. Epub 2014 Jun 5.

32.

Supervised segmentation of polycystic kidneys: a new application for stereology data.

Warner JD, Irazabal MV, Krishnamurthi G, King BF, Torres VE, Erickson BJ.

J Digit Imaging. 2014 Aug;27(4):514-9. doi: 10.1007/s10278-014-9679-y.

33.

Experimental therapies and ongoing clinical trials to slow down progression of ADPKD.

Irazabal MV, Torres VE.

Curr Hypertens Rev. 2013 Feb;9(1):44-59. Review.

34.

Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseases.

Leung N, Gertz M, Kyle RA, Fervenza FC, Irazabal MV, Eirin A, Kumar S, Cha SS, Rajkumar SV, Lacy MQ, Zeldenrust SR, Buadi FK, Hayman SR, Nasr SH, Sethi S, Ramirez-Alvarado M, Witzig TE, Herrmann SM, Dispenzieri A.

Clin J Am Soc Nephrol. 2012 Dec;7(12):1964-8. doi: 10.2215/CJN.11161111. Epub 2012 Sep 27.

35.

Low- and high-molecular-weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study.

Irazabal MV, Eirin A, Lieske J, Beck LH, Sethi S, Borland TM, Dillon JJ, Nachman PH, Nasr SH, Cornell LD, Leung N, Cattran DC, Fervenza FC.

Nephrol Dial Transplant. 2013 Jan;28(1):137-46. doi: 10.1093/ndt/gfs379. Epub 2012 Sep 17.

36.

Somatostatin analog therapy for severe polycystic liver disease: results after 2 years.

Hogan MC, Masyuk TV, Page L, Holmes DR 3rd, Li X, Bergstralh EJ, Irazabal MV, Kim B, King BF, Glockner JF, Larusso NF, Torres VE.

Nephrol Dial Transplant. 2012 Sep;27(9):3532-9. doi: 10.1093/ndt/gfs152. Epub 2012 Jul 6.

37.

Acute kidney injury during leukocyte engraftment after autologous stem cell transplantation in patients with light-chain amyloidosis.

Irazabal MV, Eirin A, Gertz MA, Dispenzieri A, Kumar S, Buadi FK, Lacy MQ, Hayman SR, Dingli D, Hogan WJ, Gastineau DA, Glavey SV, Amer H, Leung N.

Am J Hematol. 2012 Jan;87(1):51-4. doi: 10.1002/ajh.22202. Epub 2011 Nov 11.

38.

Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney.

Eirin A, Irazabal MV, Gertz MA, Dispenzieri A, Lacy MQ, Kumar S, Sethi S, Nasr SH, Cornell LD, Fidler ME, Fervenza FC, Leung N.

Nephrol Dial Transplant. 2012 Mar;27(3):1097-101. doi: 10.1093/ndt/gfr381. Epub 2011 Nov 7.

PMID:
22067518
39.

Extended follow-up of unruptured intracranial aneurysms detected by presymptomatic screening in patients with autosomal dominant polycystic kidney disease.

Irazabal MV, Huston J 3rd, Kubly V, Rossetti S, Sundsbak JL, Hogan MC, Harris PC, Brown RD Jr, Torres VE.

Clin J Am Soc Nephrol. 2011 Jun;6(6):1274-85. doi: 10.2215/CJN.09731110. Epub 2011 May 5.

40.

Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease.

Irazabal MV, Torres VE, Hogan MC, Glockner J, King BF, Ofstie TG, Krasa HB, Ouyang J, Czerwiec FS.

Kidney Int. 2011 Aug;80(3):295-301. doi: 10.1038/ki.2011.119. Epub 2011 May 4.

41.

Rituximab therapy in idiopathic membranous nephropathy: a 2-year study.

Fervenza FC, Abraham RS, Erickson SB, Irazabal MV, Eirin A, Specks U, Nachman PH, Bergstralh EJ, Leung N, Cosio FG, Hogan MC, Dillon JJ, Hickson LJ, Li X, Cattran DC; Mayo Nephrology Collaborative Group.

Clin J Am Soc Nephrol. 2010 Dec;5(12):2188-98. doi: 10.2215/CJN.05080610. Epub 2010 Aug 12.

42.

Acute kidney injury in patients with inactive cytochrome P450 polymorphisms.

Leung N, Eirin A, Irazabal MV, Maddox DE, Gunderson HD, Fervenza FC, Garovic VD.

Ren Fail. 2009;31(8):749-52. doi: 10.3109/08860220903118608.

PMID:
19814645
43.

Successful pregnancy and delivery of a healthy newborn despite transplacental transfer of antimyeloperoxidase antibodies from a mother with microscopic polyangiitis.

Silva F, Specks U, Sethi S, Irazabal MV, Fervenza FC.

Am J Kidney Dis. 2009 Sep;54(3):542-5. doi: 10.1053/j.ajkd.2009.02.016. Epub 2009 Apr 23.

PMID:
19395136

Supplemental Content

Loading ...
Support Center